Rapalogs and mTOR inhibitors as anti-aging therapeutics
Open accessThe DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Abstract
Rapamycin, an inhibitor of mechanistic target of rapamycin (mTOR), has the strongest experimental support to date as a potential anti-aging therapeutic in mammals. Unlike many other compounds that have been claimed to influence longevity, rapamycin has been repeatedly tested in long-lived, genetically heterogeneous mice, in which it extends both mean and maximum life spans. However, the mechanism that accounts for these effects is far from clear, and a growing list of side effects make it doubtful that rapamycin would ultimately be beneficial in humans. This Review discusses the prospects for developing newer, safer anti-aging therapies based on analogs of rapamycin (termed rapalogs) or other approaches targeting mTOR signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rapamycin and its analogs (so-called ‘rapalogs’) suppress the SASP by inhibiting mTOR and appear to extend healthspan and lifespan in mice105,108,109.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [105]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In fact, reviewing the effects of other interventions like rapalogs and sirtuins also shows that they may be impacting many of the similar hallmarks of aging (Lamming et al. 2013, Grabowska et al. 2017).”
From Benefits of Metformin in Attenuating the Hallmarks of Aging (2020) · cites this paper as Lamming et al. 2013
The cited source says what the claim attributes to it.
In the citing paper
“Many of the side effects of rapamycin, which include immunosuppression, hyperlipidemia and hyperglycemia, have raised concerns about the feasibility of using rapamycin to promote healthy longevity in humans and slowed clinical evaluation of mTOR inhibitors for diseases of aging 26.”
From Targeting the biology of aging with mTOR inhibitors (2023) · cites this paper as [26]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“SASP inhibitors (senomorphics) can directly or indirectly attenuate the SASP of senescent cells by inhibiting transcription factor nuclear factor (NF)-κB, the JAK-STAT signal transduction pathway, the serine/threonine protein kinase mTOR, mitochondrial complex-1-related or 4-related targets, or other pathways involved in the induction and maintenance of the SASP103–106.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [105]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“no senolytic compounds developed to date are able to eliminate all types of senescent cells; further they retain a low level of toxicity to young normal cells (Lamming et al., 2013).”
From Single senescent cell sequencing reveals heterogeneity in senescent cells induced by telomere erosion (2019) · cites this paper as Lamming et al., 2013
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1
Kim, J., Kundu, M., Viollet, B., & Guan, K.-L. (2011) · Nature Cell Biology · doi:10.1038/ncb2152 · Cited by 7,227 · cited 2×
“the autophagy-initiating kinase ULK1 (46).”
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 14×
“We might therefore expect other compounds that activate AMPK to specifically inhibit mTORC1 activity.”
BackgroundInfluentialAMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849 · cited 1×
“phorylation of TSC2 and the inhibitory phosphorylation of raptor, an essential component of mTORC1 (92, 93).”
BackgroundNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766
Sancak, Y., Bar-Peled, L., Zoncu, R., Markhard, A. L., Nada, S., & Sabatini, D. M. (2010) · Cell · doi:10.1016/j.cell.2010.02.024 · Cited by 2,464 · cited 1×
“The Rag proteins activate mTORC1 by localizing mTORC1 to the lysosome via interaction with the ragulator complex (110).”
BackgroundSelf-citationProlonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365 · cited 1×
“This effect was first observed in certain cultured cell lines (73), and we have recently shown that it also occurs in vivo in multiple tissues including liver, muscle, and adipose (see Figure 2).”
BackgroundSelf-citationLaplante, M., & Sabatini, D. M. (2009) · Journal of Cell Science · doi:10.1242/jcs.051011 · Cited by 2,170 · cited 1×
“through a wide variety of signaling mechanisms and have roles in many aspects of physiology, which have been reviewed in depth (9).”
BackgroundSelf-citationFranceschi, C., Capri, M., Monti, D., Giunta, S., Olivieri, F., Sevini, F., Panourgia, M. P., Invidia, L., Celani, L., Scurti, M., et al. (2007) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2006.11.016 · Cited by 2,087 · cited 1×
“Chronic, low-grade inflammation is a feature of aging, and almost every chronic disease has an inflammatory component (71).”
BackgroundA mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053 · cited 2×
“Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer.”
Background
Cited by
Items 501–565 of 565
Chemical Genetic Analyses of Kānuka ('Kunzea ericoides') Extracts
Blockley-Powell, S. (2019) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.22807040
El envejecimiento: ¿Podemos frenarlo? Autofagia/Nutrición. Reprogramación Celular Segunda Parte
Prof. Jubilado, U. C. D. V., & Garrido, M. D. R. (2023) · Revista de la Facultad de Farmacia · doi:10.54305/rffucv.2023.86.3.16
Goswami, A. (2024) · Journal of medical pharmaceutical and allied sciences · doi:10.55522/jmpas.v13i1.6243
Lignan 7-hydroxymatairesinol in the context of post-genomic pharmacology
Николаевна, Р. А., Torshin, I. Y., Громова, О. А., & Galustyan, A. N. (2024) · FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology · doi:10.17749/2070-4909/farmakoekonomika.2024.240
Lim, S. E. (2024) · International Journal of Innovative Science and Research Technology (IJISRT) · doi:10.38124/ijisrt/ijisrt24may2391
Николаевна, Р. А., Torshin, I. Y., & Громова, О. А. (2024) · Pharmacokinetics and Pharmacodynamics · doi:10.37489/2587-7836-2024-1-66-76
Targeting autophagy with pharmacological small molecules to treat human diseases
Wang, G., Fu, Y., & Liu, B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23932-8.00010-8
Zhou, H., Li, X., & Liu, D. (2025) · Doklady Biochemistry and Biophysics · doi:10.1134/s1607672924601008
“Researchers have identified two mTORC complexes: mTORC1 and mTORC2 [18–20].”
Tóth, B. I., Bazeli, B., Janssens, A., Lisztes, E., Racskó, M., Kelemen, B., Herczeg, M., Nagy, T. M., Kövér, K. E., Mitra, A., et al. (2025) · eLife · doi:10.7554/elife.97341.2.sa0
Direct modulation of TRPM8 ion channels by rapamycin and analog macrolide immunosuppressantsPreprint
Tóth, B. I., Bazeli, B., Janssens, A., Lisztes, E., Racskó, M., Kelemen, B., Herczeg, M., Nagy, T. M., Kövér, K. E., Mitra, A., et al. (2025) · eLife · doi:10.7554/elife.97341.2
The Role of Kinase Inhibitors in Healthy Aging: Potential Pathways and Challenges
Boro, A., Shanmugasundaram, R., Arumugam, S., Vanaraj, M., Rangarajan, S., Babu, N., Abidharini, J. D., & Anand, A. V. (2025) · IGI Global eBooks · doi:10.4018/979-8-3693-9730-5.ch013
ENVELHECIMENTO DEMOGRÁFICO - PROBLEMA OU DESAFIO?
Magalhães, C. P., Antão, C., Bemposta, M., & da Cruz, J. R. M. (2025) · doi:10.22533/at.ed.79225160601
Why We Die: Evolution, Energetic Prioritization, and the Architecture of AgingPreprint
Hansen, T. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5371008
Metronomic Chemotherapy in the Treatment of Infantile Parotid Hemangioma – A Case Report
Dadaboev, A., Shukurova, M., Madrakhimov, M., & Kotamjani, S. S. (2025) · International Medical Case Reports Journal · doi:10.2147/imcrj.s534276
“21–23 It is evident from the scientific literature that PROS syndrome, also known as PIK3CA-Related Overgrowth Spectrum disorders, is also associated with the mutation in the PI3K/Akt/mTOR signaling pathway.”
Chen, X., Chen, J., Liu, S., & Yu, D. (2025) · The FASEB Journal · doi:10.1096/fj.202501447r
Metabolic health and intermittent fasting: implications for age-related disorders
Ghosh, S., Singh, K. K., Raghunath, M., & Sinha, J. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30060-8.00007-8 · Cited by 6
Diapause and aging: Two opposing yet intertwined biological phenomena
Khodajou-Masouleh, H., & Ghanbari, S. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102998 · Cited by 2
Wijesinha, M. A., Terrin, M. L., Pham, S. M., & Iacono, A. T. (2025) · JHLT Open · doi:10.1016/j.jhlto.2025.100469
“22 Regarding BOS specifically, multiple mechanisms by which mTOR inhibitors may be beneficial have been demonstrated in pre-clinical studies.”
Autophagy in the Onset of Atrial Fibrillation
Troncoso, R., Verdejo, H., Quiroga, C., Pedrozo, Z., Corbalan, R. L., & García, L. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801033-4.00012-6
Makki, K. (2014) · theses.fr (ABES) · doi:10.70675/23365297z0518z4469za96czcd48d5e422a4
“Un exemple de molécules inhibant les deux complexes mTOR (350).”
Raynes, Y., Santiago, J. C., Lemieux, F. A., Darwin, L., & Rand, D. M. (2024) · Figshare · doi:10.6084/m9.figshare.26758375
Alfatah, M., Zhang, Y., Naaz, A., Cheng, T. Y. N., & Eisenhaber, F. (2024) · Figshare · doi:10.6084/m9.figshare.26671203
Raynes, Y., Santiago, J. C., Lemieux, F. A., Darwin, L., & Rand, D. M. (2024) · Figshare · doi:10.6084/m9.figshare.26758369
Raynes, Y., Santiago, J. C., Lemieux, F. A., Darwin, L., & Rand, D. M. (2024) · Figshare · doi:10.6084/m9.figshare.26758360
Raynes, Y., Santiago, J. C., Lemieux, F. A., Darwin, L., & Rand, D. M. (2024) · Figshare · doi:10.6084/m9.figshare.26758345
Raynes, Y., Santiago, J. C., Lemieux, F. A., Darwin, L., & Rand, D. M. (2024) · Figshare · doi:10.6084/m9.figshare.26758354
Raynes, Y., Santiago, J. C., Lemieux, F. A., Darwin, L., & Rand, D. M. (2024) · Figshare · doi:10.6084/m9.figshare.26758336
Raynes, Y., Santiago, J. C., Lemieux, F. A., Darwin, L., & Rand, D. M. (2024) · Figshare · doi:10.6084/m9.figshare.26758327
Raynes, Y., Santiago, J. C., Lemieux, F. A., Darwin, L., & Rand, D. M. (2024) · Figshare · doi:10.6084/m9.figshare.26758342
Raynes, Y., Santiago, J. C., Lemieux, F. A., Darwin, L., & Rand, D. M. (2024) · Figshare · doi:10.6084/m9.figshare.26758333
Raynes, Y., Santiago, J. C., Lemieux, F. A., Darwin, L., & Rand, D. M. (2024) · Figshare · doi:10.6084/m9.figshare.26758330
Raynes, Y., Santiago, J. C., Lemieux, F. A., Darwin, L., & Rand, D. M. (2024) · Figshare · doi:10.6084/m9.figshare.26758348
Raynes, Y., Santiago, J. C., Lemieux, F. A., Darwin, L., & Rand, D. M. (2024) · Figshare · doi:10.6084/m9.figshare.26758357
Raynes, Y., Santiago, J. C., Lemieux, F. A., Darwin, L., & Rand, D. M. (2024) · Figshare · doi:10.6084/m9.figshare.26758366
Raynes, Y., Santiago, J. C., Lemieux, F. A., Darwin, L., & Rand, D. M. (2024) · Figshare · doi:10.6084/m9.figshare.26758372
Raynes, Y., Santiago, J. C., Lemieux, F. A., Darwin, L., & Rand, D. M. (2024) · Figshare · doi:10.6084/m9.figshare.26507305
Raynes, Y., Santiago, J. C., Lemieux, F. A., Darwin, L., & Rand, D. M. (2024) · Figshare · doi:10.6084/m9.figshare.26758363
Raynes, Y., Santiago, J. C., Lemieux, F. A., Darwin, L., & Rand, D. M. (2024) · Figshare · doi:10.6084/m9.figshare.26758339
Raynes, Y., Santiago, J. C., Lemieux, F. A., Darwin, L., & Rand, D. M. (2024) · Figshare · doi:10.6084/m9.figshare.26758351
Raynes, Y., Santiago, J. C., Lemieux, F. A., Darwin, L., & Rand, D. M. (2024) · Figshare · doi:10.6084/m9.figshare.26507211
Dysregulated DJ1-Mediated Translation in Alzheimer's Disease
Uneri, A. (2018) · WakeSpace Scholarship (Wake Forest University)
Akbar, A., Nawaz, S., Iqbal, Q. M., Ashraf, E., Mazhar, M., & Irum, B. (2025) · Indus journal of bioscience research. · doi:10.70749/ijbr.v3i12.2684
Insights in Molecular Mechanisms of Aging 2022
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-7533-8
Aspirin recapitulates features of caloric restriction
Castoldi, F. (2018) · theses.fr (ABES) · doi:10.70675/02f5de46z9573z4f0dz9b29z3fa5274e9088
Veronika Urbán, S., Balázs, V., Kocsis, L., Ceglédi, A., & Mikala, G. (2026) · Hematológia–Transzfuziológia · doi:10.1556/2068.2026.00238
Emerging role of cellular senescence in peritumoral microenvironment on tumor progression
Zhou, M., Guan, B., Han, A., Zhao, S., Zhang, X., & Yan, D. (2025) · Geromedicine · doi:10.70401/geromedicine.2026.0021
TORC1 integrates metabolic state transitions during agingPreprint
Cheng, T. Y. N., Naaz, A., 高铭彤, Hao, W., Zhang, Y., Cui, L., Lin, J. J., Yogasundaram, S., Faidzinn, N. A., Victoria, O. Y. Q., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.18.726092
“Analysis of the top 200 up-and downregulated genes per perturbation revealed substantial overlap in functional pathway enrichment within individual cell types despite limited gene-level concordance (Figures 6B–6E and S32–S39; Table S2; Extended Data 18–25) .”
Aggour, Y., & Salguero‐Gómez, R. (2026) · Frontiers in Aging · doi:10.3389/fragi.2026.1800288
“Within the nutrient-sensing literature, targeted pathway inhibition prevails (Lamming et al., 2013).”
InfluentialWu, B., Wang, L.-J., Godbole, A. A., Han, J. H., Keebaugh, E. S., Chavez, G., Sedore, C. A., Coleman-Hulbert, A. L., Johnson, E., Phillips, P. C., et al. (2026) · The Journals of Gerontology Series A · doi:10.1093/gerona/glag165
Johnson, E., Sedore, C. A., Coleman-Hulbert, A. L., Onken, B., Achanta, M., Song, Y., Cortopassi, G. A., Lithgow, G. J., Driscoll, M., & Phillips, P. C. (2026) · PubMed Central · doi:10.17912/micropub.biology.002198
“…have found that genetic inhibition of mTORC1 or its downstream signaling pathways extends lifespan (Vellai et al., 2003; Kaeberlein et al., 2005; Lamming et al., 2013), whereas inhibition of mTORC2 has been associated with decreased lifespan in worms and mice (Lamming et al., 2012; Lamming et…”
Zhavoronkov, A. A., & Mishra, B. (2026) · Aging · doi:10.18632/aging.206422
Maz, M. P., Zhang, L., Ma, F., Gharaee‐Kermani, M., Klein, B., Moallemian, R., Nguyen, N. T. K., Cai, Y., Loftus, S. N., Billi, A. C., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adw1914
Barone, S., Zahedi, K. A., & Soleimani, M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.22.753536
“Currently, rapalogs such as everolimus are the most effective treatments for TSC (3), but their efficacy is limited by serious side effects (10, 11), including recurrence of kidney lesions upon discontinuation (3, 9).”
Alves, L. N. R., dos Santos, E. D. V. W., Trabach, R. S. D. R., Meira, D. D., & Louro, I. D. (2026) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2026.131009
Advances in p53 Therapies for Oral Squamous Cell Carcinoma: A Literature Review
Aguilar, V. M. M., Trejo‐Solís, C., Magaña-Maldonado, R., Chac-Couoh, K. E., Pitones-Rubio, V., Gallardo‐Pérez, J. C., Carrillo-Ávila, B. A., Camarena, A. H., & Chávez-Cortéz, E. G. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48101013
“Rapalogs are first-generation inhibitors of the mechanistic target of rapamycin (mTOR), including rapamycin (RAD001) and temsirolimus (CCI-779) [61]. mTOR is a kinase that belongs to the mTORC1 complex that regulates macromolecular synthesis and cell growth and is implicated in cancer etiology…”
BindingDB Entry 50012662: 4-(Difluoromethyl)-5-(4-((3
BindingDB (2022) · UC San Diego · doi:10.7270/q2sn0dns
Delivery Strategies Targeting Senescent Cells: From Precise Elimination to Functional Remodeling
Liu, Z., Hu, Z., Xia, A., Wang, Q., Li, L., Minglu, Z., Xiang, Y., & Ruan, J. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18111376
Tan, E. P., Ambaye, L., Mahul‐Mellier, A., Zhang, Y., Martínez-Botía, P., Labra, S. R., Massey, L. A., Gao, Z., Ahmed, Z., Nugroho, K., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.30.760220
Metadata
- Authors
- Lamming, D. W., Ye, L., Sabatini, D. M., & Baur, J. A.
- Affiliations
- Howard Hughes Medical Institute (US)
- University of Pennsylvania (US)
- Broad Institute (US)
- Corresponding author
- Baur, Joseph A.
- Venue
- Journal of Clinical Investigation
- Published
- 2013-03-01
- Volume
- 123
- Issue
- 3
- Pages
- 980-989
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3582126
- OpenAlex
- W2129902630
- Cited by
- 531
- References
- 133
- Citations by year
- 2026: 18 · 2025: 32 · 2024: 42 · 2023: 37 · 2022: 41 · 2021: 25 · 2020: 28 · 2019: 44 · 2018: 46 · 2017: 38 · 2016: 57 · 2015: 61 · 2014: 46 · 2013: 16
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Ellison Medical Foundation
- American Federation for Aging Research
- American Heart Association
- Charles A. King Trust
- Starr Foundation
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- National Institutes of Health
- National Institute on Aging (K99AG041765)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- rapamycin, rapalogs, mTOR inhibitors, anti-aging therapeutics, longevity, lifespan extension, mTOR signaling, genetically heterogeneous mice, adverse drug reactions
- MeSH terms
- Aging, Animals, Anti-Inflammatory Agents, Antineoplastic Agents, Autophagy, Humans, Metformin, Neoplasms, Stem Cells, Sirolimus, TOR Serine-Threonine Kinases, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.